Integrating ESAGE with EHR Data Using Machine Learning for the Early Detection and Monitoring of Cognitive Impairment in Individuals

Last updated: March 18, 2025
Sponsor: Douglas Scharre
Overall Status: Active - Enrolling

Phase

N/A

Condition

Dementia

Memory Loss

Alzheimer's Disease

Treatment

electronic self administered gerocognitive examination (eSAGE)

Clinical Study ID

NCT06017505
2023H0249
  • Ages > 50
  • All Genders

Study Summary

The goal of this observational trial is to leverage the electronic Self-Administered Gerocognitive Examination (eSAGE), a variety of metadata (a set of data that describes and gives information about other data) collected during eSAGE testing, electronic health records (EHR) information, and advanced machine learning (ML) techniques to develop a new tool that can aid in early-stage prediction of individuals with cognitive impairments.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Males and females 50 years of age and over who complete the eSAGE as part oftheir office visit at the Center for Cognitive and Memory Disorders.

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 1486
Treatment Group(s): 1
Primary Treatment: electronic self administered gerocognitive examination (eSAGE)
Phase:
Study Start date:
September 01, 2024
Estimated Completion Date:
September 30, 2027

Study Description

This is a retrospective and prospective record review trial for patients who are followed at the Center for Cognitive and Memory Disorders.

eSAGE assessment data (including cognitive data, behavioral data, timing data and other metadata) as well as varying amount of electronic health records (EHR) data will be collected on all eligible subjects. Machine learning techniques with feature selection will identify important EHR variables to determine what may be useful for the prediction of cognitive impairment.

Based on the EHR analysis additional questions will be added to the eSAGE to make an enhanced eSAGE version (eSAGE+). The goal of the eSAGE+ is to facilitate the identification of cognition impairment, and ultimately have a translational impact on Alzheimer's disease (AD) identification and management.

Connect with a study center

  • Nicole Vrettos

    Columbus, Ohio 43123
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.